Evidence map›Paper›PMID 28093577›Full record

ArticleCurrent behavioral neuroscience reports2016

Epigenetic Research in Neuropsychiatric Disorders: the "Tissue Issue".

Kelly M Bakulski, Alycia Halladay, Valerie W Hu, Jonathan Mill, M Daniele Fallin

Abstract read
In one paragraph

Article in Current behavioral neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Blood DNA methylation as a potential biomarker of dementia: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018
    Pooled it
  8. Trial
  9. The role ofEpigenetics · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. InvestigatingBrain sciences · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kelly M BakulskiDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Alycia HalladayAutism Science Foundation, New York City, New York, USA; Department of Pharmacology and Toxicology, Rutgers University, New Brunswick, New Jersey, USA.
Valerie W HuDepartment of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, George Washington University, Washington, DC, USA.
Jonathan MillUniversity of Exeter Medical School, University of Exeter, Exeter, UK; Institute for Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
M Daniele FallinDepartment of Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA; Wendy Klag Center for Autism and Developmental Disabilities, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Funding

Environment, The Perinatal Epigenome, and Risk for Autism and Related DisordersR01ES017646 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI FALLIN, M DANIELE, FEINBERG, ANDREW P. · 2009 to 2013
$8.7M
Prenatal exposure to metals and risk for Autism Spectrum Disorder in MARBLES and EARLIR01ES025531 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI VOLK, HEATHER E · 2016 to 2020
$3.2M
A multi-faceted approach to epigenomic profiling in Alzheimer's disorderR01AG036039 · NIA · KING'S COLLEGE LONDON · PI MILL, JONATHAN · 2009 to 2012
$1.7M
Are endocrine disrupting compounds environmental risk factors for autism?R21ES023061 · NIEHS · GEORGE WASHINGTON UNIVERSITY · PI HU, VALERIE W · 2014 to 2015
$436k
Medical Research Council MR/K013807/1NIA NIH HHS R01 AG036039NIEHS NIH HHS R01 ES017646NIEHS NIH HHS R01 ES025531NIEHS NIH HHS R21 ES023061
6 · The paper itself

Abstract

purpose of reviewEvidence has linked neuropsychiatric disorders with epigenetic marks as either a biomarker of disease, biomarker of exposure, or mechanism of disease processes. Neuropsychiatric epidemiologic studies using either target brain tissue or surrogate blood tissue each have methodological challenges and distinct advantages. RECENT

findingsBrain tissue studies are challenged by small sample sizes of cases and controls, incomplete phenotyping, post-mortem timing, and cellular heterogeneity, but the use of a primary disease relevant tissue is critical. Blood-based studies have access to much larger sample sizes and more replication opportunities, as well as the potential for longitudinal measurements, both prior to onset and during the course of treatments. Yet, blood studies also are challenged by cell-type heterogeneity, and many question the validity of using peripheral tissues as a brain biomarker. Emerging evidence suggests that these limitations to blood-based epigenetic studies are surmountable, but confirmation in target tissue remains important. SUMMARY: Epigenetic mechanisms have the potential to help elucidate biology connecting experiential risk factors with neuropsychiatric disease manifestation. Cross-tissue studies as well as advanced epidemiologic methods should be employed to more effectively conduct neuropsychiatric epigenetic research.

Indexed as

BloodDNA methylationEpigeneticsNeuropsychiatric disordersTissue

Identifiers

PMID28093577
PMCPMC5235359

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.